NeuBase Therapeutics Announces Appointment of Cancer Biologist and RNA Therapeutics Specialist Steven Dowdy, Ph.D., to Scientific Advisory Board
October 11, 2019 08:00 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH, Oct. 11, 2019 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense therapies to...
NeuBase Therapeutics to Present at the Chardan 3rd Annual Genetic Medicines Conference
September 26, 2019 09:08 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH, Sept. 26, 2019 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense therapies to...
NeuBase Therapeutics Hosting Key Opinion Leader Meeting on Huntington's Disease and PATrOL™-Enabled Therapy on September 16th
September 09, 2019 08:39 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH, Sept. 09, 2019 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense therapies to...
NeuBase Therapeutics Reports Financial Results for the Fiscal Third Quarter of 2019
August 14, 2019 16:05 ET
|
NeuBase Therapeutics, Inc.
Completed two financings in July 2019 totaling approximately $14 million in gross proceeds with participation from institutional investors including Greenlight Capital PITTSBURGH, Aug. ...
NeuBase Therapeutics to Ring the NASDAQ Closing Bell Today
August 07, 2019 08:00 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH, Aug. 07, 2019 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” and the “Company”), a biotechnology company developing next generation antisense therapies to...
NeuBase Therapeutics Announces Addition of Industry Pioneer Dr. Samuel Broder and World-Renowned Geneticist Dr. George Church to Scientific Advisory Board
July 30, 2019 08:00 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH, July 30, 2019 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense therapies to...
NeuBase Therapeutics Appoints Danith Ly, Ph.D. as Chief Scientific Officer
July 24, 2019 08:00 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH, July 24, 2019 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense therapies to...
NeuBase Therapeutics Initiates Trading on NASDAQ Under Ticker Symbol “NBSE”
July 15, 2019 10:20 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH, July 15, 2019 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” and the “Company”), a biotechnology company developing next generation antisense therapies to...
NeuBase Therapeutics Closes Merger Transaction with Ohr Pharmaceutical
July 12, 2019 09:28 ET
|
NeuBase Therapeutics, Inc.
Company expects to initiate trading on NASDAQ Under Ticker Symbol “NBSE” effective July 15, 2019Company completes previously announced financing of approximately $9 million immediately prior to...
NeuBase Therapeutics to Participate in Roth RNA Revolution Conference
July 11, 2019 08:00 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH, July 11, 2019 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (“NeuBase”), a biotechnology company developing next generation antisense therapies to address genetic diseases, today...